Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines
Open Access
- 1 January 2018
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 8 (9) , 2300-2312
Abstract
Deposition of liposomal drugs into solid tumors is a potentially rate-limiting step for drug delivery and has substantial variability that may influence probability of response. Tumor deposition is a shared mechanism for liposomal therapeutics such that a single companion diagnostic agent may have utility in predicting response to multiple nanomedicines.Keywords
This publication has 27 references indexed in Scilit:
- 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast CancerClinical Cancer Research, 2017
- Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)Molecular Cancer Therapeutics, 2015
- Whole-body organ-level and kidney micro-dosimetric evaluations of 64Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primatesEJNMMI Research, 2015
- Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug ConversionCancer Research, 2014
- HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicityToxicology and Applied Pharmacology, 2012
- Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization StrategyCancer Research, 2006
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.2001
- Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid TumorsPharmacological Reviews, 1999
- A NEW CONCEPT FOR MACROMOLECULAR THERAPEUTICS IN CANCER-CHEMOTHERAPY - MECHANISM OF TUMORITROPIC ACCUMULATION OF PROTEINS AND THE ANTITUMOR AGENT SMANCS1986